• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.09
  • VXN 15.15
  • VXO 12.04
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
SGEN (Seattle Genetics Inc.)
Last Trade 69.18 Dividend/Share 0 PE Ratio -42.44
Date April 18-2019 Dividend Yield 0.000 Return on Assets -18.7
Change -1.62 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -1.43 Price/Sale 22.166
Ask null LatestEPS Date 2018-12-31 Price to Book 8.74
Volume null EPS ttm -1.630 Institutional % 130.3
Avg Volume 0.97M Shares Outstanding 160.95M Insider % 1.6
Open 70.95 Float 158.46M Short Ratio null
Prev Close 70.8 Return On Equity -22.82 5 Year Change % 0.752
High 72 Consensus EPS -0.28 2 Year Change % 0.059
Low 68.44 No. of Estimate 7.000 1 Year Change % 0.389
52 Week High 84.37 EPS Surprise $ null YTD Change % 0.203
52 Week Low 47.75 EPS Surprise Percent 0 6 Month Change % -0.028
52 Week Change 36.208 EBITDA 0M 3 Month Change % -0.022
50 Day MA 72.9096 Revenue 0M 1 Month Change % -0.081
200 Day MA Gross Profit 0M 5 Day Change % -0.114
Market Cap 11134.84M Cash 0M 30 Day Change % -0.001
Beta 2.263855 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.